In breakthrough, scientists reprogram skin cells into ESCs
On FierceBioResearcher.com today, you'll see a report that Dolly creator Ian Wilmut is giving up on cloning and focusing on harvesting stem cells from skin tissue for biomedical research work. You'll get a better understanding why he's making the switch with the publication today of two studies showing that skin cells were reprogrammed into replicas of embryonic stem cells by simply adding four genes. The approach, reported by two sets of scientists, allows researchers to create stem cells that act in the kind of blank-slate fashion of ESCs, without the controversial destruction of human embryos. There is the possibility that introducing the genes in the way that's being reported today could create risks, especially if a cancer gene is being added into the skin cell equation. But the scientists say that it won't take long to perfect the technology, opening up the entire field of stem cell research in one fell swoop.
"Everyone was waiting for this day to come," the Rev. Tadeusz Pacholczyk, director of education at the National Catholic Bioethics Center, told The New York Times. "You should have a solution here that will address the moral objections that have been percolating for years."
- read the article in The New York Times
Related Articles:
Dolly creator scraps cloning, takes new approach. Report
Ian Wilmut discusses how regulations affect stem cell science. Report
Mature stem cells prove effective in cloning. Report
Single-parent stem cells may skirt cloning controversy. Report
Researcher promises cloned embryonic stem cells. Report
Comments
There is a small yet very experienced stem cell company called Stem Cell Innovations (SCLL) that owns one of the only two patents that exist regarding stem cells. A university in Wisconsin I believe holds the embryonic stem cell patent while SCLL owns the mesachymal stem cell patent that can produce all cells of the body. This company also is a major player in drug toxicity testing on the liver and bears watching especially at such an incredible price.
Agreed, I've been following this company for over a year. There experience will enable them to be successful in the stem cell field,once it gets going after the presidential election. The price is definetly right.
Post new comment
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight

